SEC Form 4 · accession 0001638599-17-000293
AYTU BIOPHARMA, INC · AYTU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gary Cantrell
Director
Period of report
Mar 16, 2017
Accepted (ET)
Mar 17, 2017 · 4:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001385818
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 135,416 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option GrantF2 | $3.23 | Mar 16, 2017 | D | 15,000 | D | — | Jul 12, 2026 | Common Stock | 15,000 | 0 | D |
| Employee Stock Option GrantF2 | $0.82 | Mar 16, 2017 | A | 15,000 | A | — | Jul 12, 2026 | Common Stock | 15,000 | 15,000 | D |
| Warrant to Purchase Common Stock | $1.86 | holding | — | — | — | Nov 2, 2017 | Nov 2, 2021 | Common Stock | 33,333 | 0 | D |
| Warrant to Purchase Common STock | $6.00 | holding | — | — | — | May 6, 2016 | May 6, 2021 | Common Stock | 3,750 | 0 | D |
Explanation of responses
- F1Of these shares, 65,000 are restricted shares that vest on July 12, 2026, subject to earlier vesting in certain situations.
- F225% vests on September 30, 2016, December 31, 2016, March 31, 2017 and June 30, 2017, subject to the Grantee's continued service as a director on such dates.
- F3These two transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option.